Scenario wins: cassi (84) lewinke-thinking-bot (40) Panshul42 (28) SynapseSeer (17) hayek-bot (15) pgodzinbot (12)
Clarifications on resolution methodology: I’ll use Yahoo Finance adjusted closing prices, which account for stock splits and reverse splits only (not dividend adjustments). “Before Aug 12, 2026” means through and including market close on August 11, 2026 at 4:00pm ET. The resolution range is unbounded. If the maximum gain exceeds 600%, I’ll resolve to the actual percentage. The NBI constituent list and market cap thresholds will be determined using Nasdaq official data as of market close on May 12, 2026.
For edge cases: If a company is acquired or delisted during the period, its highest adjusted closing price will include the final trading day before delisting. Only official daily closing prices reported by Yahoo Finance will count.
| Figure/Metric | Value | Source | Significance |
|---|---|---|---|
| NBI Index Level (May 12, 2026) | 5,998.20 | Nasdaq | The baseline index value for the forecasting period. |
| Apellis Acquisition Premium | 140% | Nasdaq News | Recent benchmark for M&A-driven price gains in the sector. |
| Moderna PDUFA Date (mRNA-1010) | Aug 5, 2026 | SEC 10-Q | A major regulatory catalyst occurring days before the resolution deadline. |
| Ionis PDUFA Date (Olezarsen) | June 30, 2026 | SEC 10-Q | A high-impact catalyst for a company with an $11B+ market cap. |
| NBI Constituent Count | 254 | Nasdaq Methodology | Indicates the size of the pool from which the maximum gainer will emerge. |
| US Inflation Rate (May 12, 2026) | 3.8% | Bureau of Labor Stats | Macroeconomic backdrop influencing sector-wide risk appetite. |
The biotechnology sector is characterized by binary risk, where stock prices are hypersensitive to clinical and regulatory outcomes. Historical data shows that mid-cap companies ($3B–$10B) are the most frequent targets for significant price movements. For example, in early 2026, Apellis Pharmaceuticals saw a 135% gain following an acquisition announcement by Biogen. In the broader NBI, companies meeting clinical milestones frequently see single-day gains of 15–40%. The period leading into May 12, 2026, has been bullish, with the NBI valued at 5,998.20 and in a ‘Golden Cross’ technical regime, which historically supports high-momentum runs in individual stocks. Previous years have shown that the ‘maximum’ 3-month gain in the NBI usually exceeds 50% due to the probability of at least one outlier success among the 250+ constituents.
My analysis focuses on the ‘maximum of many’ statistical property of this question. With approximately 254 NBI constituents, roughly 50 to 60 companies currently meet the $3B market capitalization threshold. In a three-month window, the largest gain in such a pool is rarely reflective of the average stock’s performance; instead, it is driven by extreme tail events.
I weighted three primary scenarios:
The specific concentration of catalysts between May 12 and August 12, 2026, is high. Key events include the FDA PDUFA dates for Ionis (June 30), Viridian (June 30), and Moderna (August 5). Furthermore, companies like Apogee and Viking Therapeutics are expected to release significant data in the Q2/Q3 window. Because the question resolves to the highest gain among all eligible companies, even a single company achieving a 100% gain through a buyout or breakthrough will set the resolution value, regardless of the rest of the index’s performance. The final prediction centers on a most likely value of 63.00%, reflecting the probability that at least one of these catalysts or an unannounced acquisition will produce an outsized return significantly higher than the median NBI stock’s performance.
The question asks for the maximum adjusted close percentage gain among Nasdaq Biotechnology Index constituents with market caps >= $3B over the 3‑month window May 12–Aug 12, 2026. Both forecasters model a pool of roughly 40–60 eligible names and agree that even baseline volatility across ~50 independent biotech stocks makes a very large maximum likely; their expected central values cluster around ~120–130% peak gain over the period. They both emphasize jump‑diffusion drivers (ASCO in early June, Phase 2/3 readouts, FDA actions, and M&A), with typical buyout premiums and successful clinical readouts often producing 50–180% single‑event jumps—historical examples like Cytokinetics and Viking/Apellis are cited. Because the $3B floor excludes microcaps, extreme 200%+ jumps are less common but still possible, so both teams place a long right tail out past 200–300% for exceptional paradigm‑shifting outcomes. Downside scenarios (a correlated market drawdown or suppressed peaks) produce a left tail toward roughly 40–60% or base outcomes near 80%, but these are considered less likely than the central 120–130% mode. Overall, the consensus is for a most‑likely maximum in the ~120–130% range with meaningful probability of both modester outcomes and rare, much larger outliers.
Forecast: Probability distribution:
We are forecasting the maximum peak (highest adjusted close) percentage gain over ~3 months (May 12 to Aug 12, 2026) across a fairly large eligible set: NBI constituents that also had market cap ≥$3B on May 12. This “max-over-many” structure materially lifts the expected outcome versus a single-stock return, but the ≥$3B filter materially compresses the far-right tail versus the full biotech universe (microcaps are where many 500%+ 3‑month spikes come from).
Across the analysts, Forecasters 3 and 4 look best-calibrated to the key constraints: they place the median around ~95–105% (roughly “someone about doubles”), with a thinning tail above ~300%. Forecaster 1’s lower tail is implausibly low for a maximum across ~50–120 volatile stocks over 63 trading days (e.g., a 10% chance the max is <5%), suggesting underestimation of the extreme-value/selection effect. Forecaster 2 appears systematically high (e.g., p5=42%, p50=138%), which likely overweights the frequency/magnitude of major catalysts and/or assumes unusually strong sector-wide conditions.
My synthesis keeps the central tendency close to Forecasters 3–4 (median near ~100%), pulls the lower percentiles upward versus Forecasters 1 and 3 (because the max should usually clear modest thresholds), and keeps meaningful but not dominant mass in the 200–400% region. I keep p95 well below the open upper bound (600) because a >$3B name gaining >600% by close within three months seems possible but very unlikely (<5%).
An amateur forecast commonly errs in one of two ways: (1) anchoring on typical index/sector returns (e.g., 5–15%) and missing the “maximum across many constituents” effect, or (2) anchoring on famous biotech moonshots (often microcaps) and ignoring the ≥$3B market-cap constraint and the use of closing (not intraday) highs. This forecast explicitly balances (i) extreme-value uplift from many opportunities for idiosyncratic winners over ~3 months with (ii) tail compression from the large-cap filter, yielding a higher median than broad-market intuition but a less extreme right tail than microcap-based intuition. Confidence: moderate; the outcome is dominated by hard-to-predict discrete catalysts and M&A timing.
Forecast rationale (numeric):
— Iteration 1 — The shared reasoning treats the target as a cross-sectional maximum over a fairly large set of large-cap biotech names, so the outcome is expected to be driven by one standout winner rather than the average stock. That framing leads to a highly skewed, heavy-tailed distribution: most names may post ordinary returns, but a single catalyst-rich stock could produce an outsized gain.
Overall, the forecasts converge on a view that the result will likely be dominated by a single catalyst-driven biotech outlier, with the most important uncertainty being how strong the sector’s right tail becomes before Aug. 12, 2026.
— Iteration 2 — Across the forecasts, the outcome is treated as an extreme-value problem: the question is not whether the average biotech name rises, but which single NBI constituent posts the biggest adjusted-close gain over roughly a 3-month window. The dominant reasoning is that biotech returns are highly skewed and event-driven, with the top performer often driven by a binary catalyst such as FDA approval, clinical data, or a high-premium M&A event.
The forecasts broadly agree that the largest gain among eligible NBI names is likely to come from a single catalyst-driven biotech winner, with the distribution strongly skewed to the upside but capped somewhat by the large-cap filter. The most credible outcome is a substantial triple-digit gain, while very large multi-bagger moves remain possible but low-probability.
— Iteration 3 — Across the forecasts, the main idea is that the largest adjusted closing-price gain in this NBI universe will likely be driven by one idiosyncratic winner, not by a broad sector move. The reasoning is essentially an extreme-value problem: with roughly 90+ eligible biotech names, even if most perform modestly, the maximum return over the window can be much larger because one company may benefit from a major catalyst.
The forecasts converge on a view that the biggest gain will probably come from a single catalyst-driven biotech name, with a triple-digit gain being the most plausible outcome. The market-cap threshold reduces the odds of extreme moonshots, but the combination of many eligible names and biotech’s event risk still leaves room for a very large winner.
Summary of Rationale Arguments
Mechanics of the “Running Maximum” A foundational element across the rationales is the resolution criteria, which measures the highest closing price achieved at any point during the 3-month window rather than a point-to-point return. Because the eligible cohort consists of dozens of inherently volatile biopharmaceutical stocks, statistical models (such as geometric Brownian motion) suggest that natural market variance and idiosyncratic drift alone will reliably generate a high baseline maximum gain, even in the absence of major sector news.
Structural Cohort Constraints The $\ge$ $3B market capitalization threshold effectively filters out the extreme, “lottery-like” surges frequently seen in micro-cap biotechs, as doubling a multi-billion-dollar valuation requires immense capital influx. However, the rationales note that this mid-to-large-cap transitional tier remains highly susceptible to massive upside tail events, primarily driven by binary catalysts rather than organic growth.
M&A Activity and Buyout Premiums The most heavily weighted driver for maximum gains is the prospect of Mergers and Acquisitions. The rationales highlight a macroeconomic environment highly conducive to dealmaking: Big Pharma possesses massive cash reserves and faces looming, severe patent cliffs. This dynamic heavily incentivizes the acquisition of de-risked, late-stage assets. While standard buyout premiums establish a strong expected gain, competitive bidding wars for highly coveted platforms (such as oncology or obesity/metabolic drugs) can push these premiums to exceptional historical heights.
Clinical and Regulatory Catalysts Beyond M&A, the rationales emphasize the impact of “make-or-break” clinical data and regulatory decisions scheduled during this window. Major medical conferences (like ASCO), pivotal Phase 2 and Phase 3 trial readouts, and FDA PDUFA dates serve as potent catalysts. A best-in-class clinical result or unexpected regulatory approval can trigger rapid, fundamental repricings that easily multiply a company’s market value overnight.
Short-Squeeze Potential Finally, multiple rationales identify elevated short interest among specific eligible constituents as a critical variable for outlier gains. In heavily shorted equities, any unexpected positive news—whether an earnings beat, clinical success, or M&A rumor—can trigger a violent short-covering rally, further amplifying the upward price action and potentially creating the maximum peak recorded during the window.
Question: What will be the largest adjusted closing-price gain before Aug 12, 2026 among May 12 NBI constituents with market cap ≥$3B? Final Prediction: Probability distribution:
Total Cost: extra_metadata_in_explanation is disabled Time Spent: extra_metadata_in_explanation is disabled LLMs: extra_metadata_in_explanation is disabled Bot Name: extra_metadata_in_explanation is disabled
Forecaster 1: Probability distribution:
Forecaster 2: Probability distribution:
Forecaster 3: Probability distribution:
The research investigates the potential for the largest adjusted closing-price gain among constituents of the NASDAQ Biotechnology Index (NBI) with a market capitalization of at least $3 billion, focusing on the period from May 12 to August 12, 2026. It outlines the methodology for determining the maximum percentage gain by comparing each company’s adjusted closing price on May 12, 2026, to its highest adjusted closing price before August 12, 2026. The study emphasizes the extreme-value nature of the analysis, considering a portfolio of approximately 50-70 eligible companies and the various market conditions and catalysts that could influence stock performance during this timeframe.
The research highlights the current market context, noting a strong performance in the NASDAQ and mixed results in the biotech sector, alongside an active mergers and acquisitions (M&A) environment. Key upcoming catalysts, such as FDA decisions and clinical trial results, are identified as potential drivers for significant stock price increases. Historical data on biotech gains and M&A premiums are referenced to estimate the likelihood of extreme gains, suggesting that while modest probabilities exist for individual companies, the cumulative effect across a larger pool increases the chances of at least one company achieving substantial gains. The research also acknowledges uncertainties, including the exact composition of the NBI and macroeconomic factors that could impact market volatility.
Sources used in the research include:
This question asks for the single highest percentage gain achieved by any NBI constituent with ≥$3B market cap, measured from their May 12, 2026 adjusted closing price to their highest adjusted closing price at any point before August 12, 2026. This is an extreme-value statistic across a portfolio of ~50-70 eligible companies over a ~3-month window.
Broad market backdrop:
M&A environment is highly active:
Several PDUFA dates and regulatory catalysts fall within the resolution window:
Full-year large biotech gains (2025):
Weekly gains observed recently (May 4-8, 2026):
Clinical catalyst-driven moves (2024):
M&A premium base rates:
Key insight for extreme-value estimation: The question measures the maximum across ~50-70 companies. Even if the probability of any single $3B+ biotech gaining >50% in 3 months is modest (perhaps 5-15%), across 50-70 independent draws, the probability that at least one achieves this is substantially higher. The extreme-value distribution shifts the expected maximum well above the average company’s performance.
The NBI contains ~225 constituents [11]. Filtering for $3B+ market cap likely yields approximately 50-70 companies, including large-cap names like:
No specific prediction markets were found for this exact question on Metaculus, Polymarket, or other platforms. This is a highly specialized quantitative question unlikely to attract liquid markets.
Drivers of extreme gains in the window:
Historical frequency of extreme 3-month gains among $3B+ NBI biotechs:
Reasonable range for the maximum gain:
1. Correlation Effects: The critic makes a compelling point. Biotech stocks share significant correlation through sector sentiment, FDA policy, and interest rate sensitivity. I was implicitly treating 50-70 companies as near-independent draws, but the effective number is likely 30-40. This warrants a modest downward adjustment to my median.
2. M&A Premium Selection Bias: The 77% median premium cited likely includes many smaller targets. For $3B+ companies specifically, acquirers have less leverage and deal scrutiny is higher. A more realistic range for $3B+ targets might be 50-65% premium rather than 77%.
3. Left Tail Too Tight: In a genuine bear market combined with no M&A for the eligible universe, my P0.1=6% and P1=14% were somewhat optimistic. A macro shock could limit even the best performer to 8-12% gains.
4. PDUFA Timing: Several catalysts I cited (Biogen’s August 24, Praxis September 27, Scholar Rock September 30) fall at or beyond the resolution window, so their direct impact is limited (though anticipatory moves are possible).
1. M&A Environment Remains Exceptional: The structural drivers—$1.4-1.5T Big Pharma cash, $200B patent cliff (2026-2030), and strongest M&A activity since 2019—are real and persistent. This isn’t a transient trend.
2. The $3B “Sweet Spot” Effect: As the critic actually notes, $3B+ companies represent ideal acquisition targets—proven assets with manageable deal sizes. The same filter that reduces volatility may increase M&A probability.
3. Even With Correlation, Extreme-Value Logic Applies: With 30-40 effective independent draws, the probability that at least one achieves a 50%+ gain remains substantial (likely 45-55%), supporting a median near 60%.
Looking at the specific PDUFA dates confirmed within the window (Achieve Life Sciences June 20, Capricor August 2026), I need to verify whether these companies meet the $3B threshold—they may not, which would reduce the number of high-impact catalysts for eligible companies. The M&A channel remains the more reliable path to extreme gains for the $3B+ cohort.
I’ll adjust my distribution to:
The critic’s suggested distribution is reasonable but slightly too conservative in my view. The exceptionally strong M&A environment justifies a somewhat higher median than their 58%.
Updated prediction:
Percentile 0.1: 5 Percentile 1: 12 Percentile 5: 22 Percentile 10: 28 Percentile 20: 38 Percentile 30: 46 Percentile 40: 53 Percentile 50: 60 Percentile 60: 70 Percentile 70: 82 Percentile 80: 99 Percentile 90: 130 Percentile 95: 170 Percentile 99: 290 Percentile 99.9: 490
1. Lower Tail Adjustment - AGREE The critic correctly identifies that my lower percentiles were too aggressive. With 50-70 $3B+ biotechs over 3 months, it’s nearly mathematically impossible for ALL stocks to stay below 6-10% gain at their peak. The “highest adjusted closing price” methodology captures each stock’s best moment, not end-of-period—this biases the maximum upward significantly. Random walk dynamics alone would push multiple stocks above 15%+ at some point. I should raise P0.1-P10 by 3-5 points.
2. Selection Bias in Examples - AGREE This is a strong point I hadn’t fully weighted. Nektar, Mineralys, and Lyell’s 190-218% annual gains likely occurred when these companies were below $3B market cap. The $3B filter genuinely constrains the opportunity set for extreme outcomes.
3. Upper Tail Moderation - PARTIALLY AGREE For $3B+ companies, 300%+ gains are genuinely rare. Even bidding wars typically cap around 150-200% premium. I’ll moderate P99-P99.9 somewhat.
M&A Environment Remains Key Driver: Despite the critic’s “deal indigestion” hypothesis, the patent cliff pressure ($200B 2026-2030) creates structural demand for acquisitions. Big pharma can’t simply pause—they need pipeline assets. The 2025 M&A momentum is likely to continue.
Combination Scenarios: A stock could gain 40% on positive Phase 3 data, then receive a 50% premium M&A offer, producing ~110% total gain. These compound scenarios justify maintaining meaningful probability mass above 100%.
Looking at the path-dependent nature of this question more carefully: we’re measuring the maximum point on each stock’s price path, not the endpoint. For high-volatility biotech names (30-40% annualized), the expected path maximum over 3 months is substantially positive even without fundamental catalysts. This reinforces raising the lower percentiles.
Updated prediction: Percentile 0.1: 10 Percentile 1: 17 Percentile 5: 25 Percentile 10: 32 Percentile 20: 42 Percentile 30: 50 Percentile 40: 58 Percentile 50: 66 Percentile 60: 78 Percentile 70: 91 Percentile 80: 112 Percentile 90: 145 Percentile 95: 188 Percentile 99: 295 Percentile 99.9: 465
Left Tail Inconsistency: The critic correctly identified a logical inconsistency. I stated “typical 3-month windows, at least one $3B+ biotech achieves 25-40% gain” yet assigned 10% probability to max ≤24%. This is contradictory. The left tail needs adjustment upward.
Base Rate Misapplication: The critic is right that Nektar, Mineralys, and other 200%+ gainers likely weren’t $3B+ companies at measurement start. My extreme-value anchors were contaminated by small-cap examples that don’t apply to this question’s universe.
Universe Composition Point: This is crucial. If ~40% of eligible companies are mega-caps (Amgen, Gilead, Regeneron, Vertex, etc.) that rarely see 50%+ moves, the distribution should be more concentrated than I initially modeled. The “many independent draws” intuition is weaker when 25+ of those draws are from low-volatility large-caps.
Right Tail Preservation: While I agree with modest compression, the M&A environment is exceptionally strong. Big Pharma’s $200B patent cliff and $1.4T cash reserves create genuine acquisition pressure. The $3-10B segment (~30% of universe, or 18-22 companies) remains vulnerable to premium acquisitions. A single acquisition at 80%+ premium or bidding war could easily produce 120%+ gain.
The Active M&A Year Context: 2025 being the strongest M&A year since 2019 suggests continuation through mid-2026 isn’t speculative. The critic’s P95 at 195% versus my 210% is close, but I’ll keep slightly more right-tail mass given specific catalysts (Achieve Life Sciences PDUFA June 20, Capricor August 2026).
The question measures peak adjusted closing price before Aug 12, not final closing price. This means even temporary spikes count. M&A announcements often produce an initial pop that may partially fade—but the peak captures the maximum. This subtly increases expected values versus measuring end-of-period returns.
Updated prediction:
Percentile 0.1: 5 Percentile 1: 12 Percentile 5: 24 Percentile 10: 28 Percentile 20: 36 Percentile 30: 45 Percentile 40: 54 Percentile 50: 63 Percentile 60: 76 Percentile 70: 90 Percentile 80: 112 Percentile 90: 150 Percentile 95: 198 Percentile 99: 335 Percentile 99.9: 485
Agent Forecast (numeric, confidence: low)
Base Rate: Apellis (APLS) 135% gain on Biogen’s ~140% premium acquisition (March-April 2026, just before this window) represents the recent reference for an exceptional NBI ≥$3B outcome. Typical large-biotech M&A premiums of 40-70% suggest a 50-100% maximum is common but not certain in any given 3-month window. Given ~50-70 eligible names and the elevated 2025-2026 M&A environment, P(max gain ≥100%) is plausibly in the 55-65% range, with the modal outcome straddling the 50-150% boundary.
Initial Reasoning:
Key Uncertainties:
Evidence Sources (11):
Grounding Facts (passed to reviewers): Here are 10 key grounding facts:
Draft: 50-100: 31.0%, 100-150: 22.0%, 0-50: 17.0%, 150-200: 13.0%, 200-300: 9.0%
Reviewer Panel:
Reviewer (reasoning)
The draft forecast leans heavily on unannounced M&A as the sole upside driver and cites a modal 50–150% historical gain without showing underlying frequencies. It downplays or ignores potential clinical or regulatory catalysts for mid‐cap constituents (e.g., ARWR, BNTX, PCVX) that could drive outsized moves and lacks concrete base‐rate data on how often large (>3 B) NBI firms actually see >100% gains in a three-month span. The reasoning therefore overstates the mid-tail probabilities and underestimates both downside and modest upside moves.
Objections:
Reviewer (calibration)
The draft forecast appropriately identifies M&A as the primary driver for significant gains given the lack of confirmed PDUFA dates within the resolution window. However, it may be underestimating the potential for unexpected clinical trial catalysts, particularly from companies with imminent, albeit non-PDUFA, data readouts. The analysis relies heavily on historical data without specifying its context, which could reduce its applicability.
Objections:
Reviewer (fact-checker)
4 unsupported claim(s). Verdict: minor_issues
Unsupported claims:
Adjustment Rationale:
Shifted ~9 percentage points from the 0-100% bins into the 100-300% bins to reflect three valid reviewer points: (1) the tail probability of a ≥100% maximum gain was underestimated relative to the active M&A environment and the size of the eligible universe (~50-70 names), bringing P(>100%) up to ~60% in line with the ensemble signal; (2) Viking Therapeutics’ Q3 2026 maintenance-dosing study data could plausibly land between July 1 and August 12, adding a meaningful binary catalyst I had effectively excluded; (3) unscheduled mid-stage readouts and partnership announcements across ARWR, INSM, INCY, GMAB and similar mid-caps add aggregate tail mass not captured in my draft’s PDUFA-centric framing. Confidence downgraded from medium to low because the modal-gain base rate I cited lacked rigorous historical frequency support, and the dominant gain pathway (unannounced M&A or unscheduled clinical surprise) is inherently low-information. Core thesis preserved: M&A premiums of 50-140% on a $3-12B target remain the most likely path to the realized maximum, with RVMD already partially priced and APLS gain occurring pre-window.
forecast_sdk | 787.9s | research $1.1942 + reviewers $0.0095 + reconcile $0.1639 = $1.3677
Extracted Percentile Values: {0.1: 6, 1.0: 10, 5.0: 16, 10.0: 20, 15.0: 24, 20.0: 28, 25.0: 32, 30.0: 35, 35.0: 38, 40.0: 41, 45.0: 44, 46.0: 45, 47.0: 46, 48.0: 47, 49.0: 48, 50.0: 49, 51.0: 50, 52.0: 51, 53.0: 52, 54.0: 54, 55.0: 56, 60.0: 62, 65.0: 70, 70.0: 80, 75.0: 90, 80.0: 105, 85.0: 125, 90.0: 150, 95.0: 200, 99.0: 320, 99.9: 500}
Model’s Answer:
This question asks for the maximum percentage gain achieved by any single company among dozens of NBI constituents with market cap ≥$3B, measured at their peak adjusted closing price during this 3-month window. This is fundamentally different from average returns - we’re looking for the single highest peak among 50+ eligible companies.
Eligible Universe: Research confirms dozens of NBI constituents exceed the $3B threshold, including AMGN ($178B), GILD ($166B), VRTX ($110B), REGN ($75B), ARGX ($51B), INSM ($23B), INCY ($20B), and many others.
Volatility Context: Large-cap NBI constituents show 30-50% annualized volatility. For a 3-month period, this translates to roughly 15-25% standard deviation per company.
Catalyst Environment:
Why a low outcome (~15-25%) could result:
Why a high outcome (~150-300%+) could result:
Assumption 1: No M&A acquisition of $3B+ NBI constituent occurs in this window
Assumption 2: ASCO 2026 data readouts don’t produce major positive surprises for large-cap NBI members
Assumption 3: No “black swan” positive event (unexpected breakthrough, major partnership)
With 50+ eligible companies over 3 months, normal volatility alone would push at least one stock to peak 20-35% above baseline. The active M&A environment and ASCO catalysts create meaningful upside potential. However, large-cap biotechs (≥$3B) are fundamentally less volatile than small-caps, limiting extreme outcomes.
My median estimate of ~49% reflects a high likelihood that either M&A activity or a positive ASCO readout drives at least one eligible company to meaningful gains. The 90th percentile at 150% captures acquisition scenarios, while the 99th percentile at 320% accounts for exceptional circumstances like multiple simultaneous positive catalysts.
The wide confidence interval (5th-95th: 16%-200%) reflects substantial uncertainty about which specific catalysts will materialize and which companies will benefit.
Percentile .1: 6 Percentile 1: 10 Percentile 5: 16 Percentile 10: 20 Percentile 15: 24 Percentile 20: 28 Percentile 25: 32 Percentile 30: 35 Percentile 35: 38 Percentile 40: 41 Percentile 45: 44 Percentile 46: 45 Percentile 47: 46 Percentile 48: 47 Percentile 49: 48 Percentile 50: 49 Percentile 51: 50 Percentile 52: 51 Percentile 53: 52 Percentile 54: 54 Percentile 55: 56 Percentile 60: 62 Percentile 65: 70 Percentile 70: 80 Percentile 75: 90 Percentile 80: 105 Percentile 85: 125 Percentile 90: 150 Percentile 95: 200 Percentile 99: 320 Percentile 99.9: 500
The maximum of ((highest adjusted close / May 12 close) - 1) × 100 across ~55–65 NBI constituents with market cap ≥$3B. This is an extreme-value statistic — the maximum over a population over time — which is inherently right-skewed and meaningfully above the average company’s gain.
Binary clinical/regulatory catalysts for mid-cap eligible companies (0.45): The primary driver. CGON (PIVOT-006 Phase 3 H1 2026), CELC (PDUFA July 17), CYTK (AdCom June 3 + Phase 3 June 15), PTGX (Phase 3 July 20), BIIB (PDUFA May 24), and COGT (Phase 2 June 15) all have known catalysts in-window. Positive outcomes from any one of these with high short interest creates potential 50–150% moves.
M&A premium for eligible companies (0.20): The M&A environment is described as exceptionally active — Q1 2026 totaling $813.3B, 50% above prior year [S41]. Acquisitions of large-cap biotech typically carry 35–70% premiums. With ~60 eligible companies over 91 days, estimated ~8–15% probability of at least one eligible company receiving a takeover bid.
Short squeeze amplification (0.15): Multiple eligible companies have elevated short interest — BEAM (31.5%), CRSP (26.7%), CELC (27.9%), LEGN (23.4%), IMVT (20.9%), MRNA (18%) [S26, S29, S34]. A positive catalyst hitting a high-short-interest stock amplifies the upside move substantially.
Options positioning signaling undiscovered catalysts (0.12): CGON options show 12,782 contracts of OI on $90 calls vs. 9,004 on $40 puts for June 18 expiry at IV 104–117% [S34]. CELC has $170 calls for July. XENE has large $75 July calls [S34]. These signal market expectations of large binary moves.
Extreme tail event (failed approval followed by re-rating, unexpected efficacy, or platform acquisition) (0.08): Historical biotech shows occasional 200%+ single-quarter moves even for large-cap names when a major platform thesis is validated.
Cloudlike / highly chaotic. Binary trial outcomes and FDA decisions are not predictable from historical averages in the usual sense. This question is poorly suited to narrow base-rate anchoring; the distribution is driven by rare tail events. The maximum over 60+ companies over 91 days with multiple known binary events is extremely right-skewed.
Wrong: “Average return of a biotech stock over 91 days” (~10–15%). This ignores that we’re taking a MAXIMUM across a large population with known binary catalysts.
Correct: “Maximum 91-day gain across a cohort of 50–70 large-cap biotech stocks containing multiple known Phase 3 readouts and PDUFA dates.” Historical precedents: in any active biotech quarter with several mid-cap names having binary catalysts, the maximum gain among eligible companies tends to be 40–150%+, with the tail extending much higher if an acquisition occurs.
Reference class richness: Moderate (5–20 analogues). Recent analogues: RVMD +57% in 3 days in this same cohort in April 2026; SYRE +233% over 6 months; TVTX +37% in 1 day [S29, S34]. Historical NBI maximum over quarters not formally computed, but the April 2026 quarter appears to have already generated 50–100%+ moves in eligible companies.
This is a maximum of a right-skewed distribution over a window, which itself follows an extreme-value distribution (Fréchet/heavy-tailed). Key parameters:
Scenario 1: Muted quarter — all major catalysts disappooint or come in below expectation (10%)
Scenario 2: One major FDA approval at PDUFA drives maximum (30%)
Scenario 3: Successful Phase 3 readout (CGON, CYTK, or PTGX) drives maximum (32%)
Scenario 4: M&A acquisition of eligible company at 50–100% premium (15%)
Scenario 5: Exceptional tail event — surprise positive trial + M&A, or high-short-interest stock with platform-validating data (13%)
Weighted average check: 10% × 22 + 30% × 52 + 32% × 78 + 15% × 75 + 13% × 180 = 2.2 + 15.6 + 24.96 + 11.25 + 23.4 = 77.4%
This is consistent with the expected maximum of a right-skewed distribution over 60 companies with multiple known catalysts.
Most likely to make this forecast wrong: CGON PIVOT-006 Phase 3 data comes in strongly positive before June 18 (consistent with options positioning), driving CGON from ~$69 to $120–$150+ (a 75–120% gain), which becomes the resolving maximum. This would push the answer to 80–130%.
Alternatively, an M&A bid at 100%+ premium for a smaller eligible company (e.g., XENE or COGT) would push the answer above 100%.
Timeframe sensitivity: If the window were halved (45 days), CELC and PTGX catalysts would fall outside, and fewer catalysts would fire — estimate would fall to ~50% median. If doubled (182 days), PRAX (Aug 17 PDUFA) would be included, and the maximum would likely exceed 100% with higher probability.
Percentile 1: 8 Percentile 5: 18 Percentile 10: 26 Percentile 20: 37 Percentile 40: 53 Percentile 60: 72 Percentile 80: 100 Percentile 90: 135 Percentile 95: 185 Percentile 99: 310
I’ll work through this systematically as a superforecaster.
The highest adjusted closing-price percentage gain from May 12, 2026 to any date before Aug 12, 2026 market close, among NBI constituents with ≥$3B market cap on May 12, 2026.
FDA PDUFA outcomes for eligible companies in window (weight: 0.30) — BIIB (May 24, Jul 25), CELC (Jul 17), JAZZ (Aug 25) are the primary catalysts. Approval typically drives 20-60% gains for mid-cap biotech.
Clinical trial readouts for eligible companies (weight: 0.25) — CYTK (Jun 3 AdCom + Jun 15 Phase 3), CGON (PIVOT-006 H1 2026), PTGX (Jul 20), COGT (Jun 15). Positive Phase 3 can drive 50-200%+ gains.
M&A acquisition bids (weight: 0.20) — Active M&A environment; large pharma flush with cash. Acquisition premiums typically 40-100% for biotech.
Broader biotech sector momentum (weight: 0.15) — XBI up 24.2% in 6 months; elevated but not extreme sentiment.
Short squeeze dynamics (weight: 0.10) — BEAM (31.5%), CRSP (26.7%), LEGN (23.4%), CELC (27.9%) short interest creates amplification potential.
Cloudlike — biotech maximum gains over a window are driven by rare, high-impact events (FDA decisions, trial readouts, M&A). The question asks for the maximum across a large cohort, making it an extreme value problem. Base-rate anchoring is moderately useful but must account for the fat-tailed nature of biotech returns.
Wrong class: “What does a typical large-cap biotech stock return over 3 months?” (IBB 3-month average ~5%)
Right class: “What is the maximum return achieved by ANY company in a cohort of 55-65 large-cap biotech stocks over a 91-day window?” — this is an order statistic from a fat-tailed distribution, meaningfully above the average single-stock return.
Moderate — I can reference:
The research shows p90 individual stock 21-day returns of 47-76% for the most volatile eligible names. Over 91 days with multiple catalysts, the maximum across 60+ stocks should be substantially higher.
Right-skewed / lognormal for individual stocks; the maximum over a window across a large cohort follows extreme value theory — the expected maximum is meaningfully above the median single-stock return. With ~60 eligible companies, multiple known binary catalysts (PDUFA, Phase 3 readouts), and a 91-day window, the distribution of the maximum gain is heavily right-skewed.
Key anchor points:
Scenario 1: No major catalysts fire; sector drift only (weight: 0.08)
Scenario 2: One moderate catalyst (BIIB approval, CELC approval, or one Phase 3 success) (weight: 0.35)
Scenario 3: Major mid-cap catalyst (CGON, PTGX, or COGT Phase 3 success) (weight: 0.35)
Scenario 4: Blockbuster catalyst + amplification (M&A or short squeeze) (weight: 0.17)
Scenario 5: Extreme tail event (multiple catalysts, unexpected breakthrough) (weight: 0.05)
Weighted average check: 0.08×20 + 0.35×45 + 0.35×90 + 0.17×170 + 0.05×350 = 1.6 + 15.75 + 31.5 + 28.9 + 17.5 = 95.25%
This seems reasonable given the cohort size, known catalysts, and historical comparable moves.
Most likely wrong scenario: If CGON’s PIVOT-006 data is positive and comes before June 18 (as options market implies), CGON could easily gain 100-200%+ from $69. This would push the answer well above 100%.
Given:
Percentile 1: 12 Percentile 5: 20 Percentile 10: 28 Percentile 20: 38 Percentile 40: 55 Percentile 60: 80 Percentile 80: 130 Percentile 90: 185 Percentile 95: 260 Percentile 99: 420
This forecast assesses the maximum adjusted closing-price gain among eligible Nasdaq Biotechnology Index (NBI) constituents (market cap ≥$3B) over a 91-day window.
The maximum value of ((Highest Price / May 12 Price) - 1) * 100 among ~60 eligible companies.
The exact timing of the CGON PIVOT-006 data is the biggest “known unknown.” If it slips past June 30 into late August, the “maximum” likely falls to the CELC PDUFA or a CYTK readout.
The outcome is the maximum of a sample, which follows a Generalized Extreme Value (GEV) distribution, typically right-skewed. In biotech, this is further stretched by the binary nature of catalysts.
With 91 days left, we are in the “sweet spot” for Phase 3 readouts. If the window were halved, the probability of missing the CGON or CELC catalysts would rise, lowering the expected max gain.
Percentile 1: 18.0 Percentile 5: 26.0 Percentile 10: 32.0 Percentile 20: 41.0 Percentile 40: 55.0 Percentile 60: 72.0 Percentile 80: 98.0 Percentile 90: 135.0 Percentile 95: 182.0 Percentile 99: 295.0
Forecast (percentiles, aggregated):
Per-model forecasts:
Rationale: Summary This forecast evaluates the maximum adjusted closing-price percentage gain over a roughly three-month period (May 12 to August 12, 2026) for Nasdaq Biotechnology Index (NBI) constituents with a market capitalization of at least $3 billion. The eligible pool consists of approximately 60 to 80 companies. A median estimate of 95% reflects the statistical properties of this specific metric and the fundamental drivers of biotechnology equities. Measuring the peak intra-period gain—the highest daily close during the window rather than the end-of-period return—across dozens of highly volatile stocks naturally inflates the expected maximum. In any given quarter, it is highly probable that at least one of these mid-to-large-cap companies will experience a significant catalyst. The primary drivers for extreme right-tail performance are mergers and acquisitions (M&A), which historically carry premiums of 50% to 105% for multi-billion dollar targets, and major clinical milestones, such as transformative Phase 3 readouts or unexpected FDA approvals. Historical analogs like Insmed, Viking Therapeutics, Summit Therapeutics, Madrigal, and Cytokinetics demonstrate that $3B+ biotechs can post 80% to over 200% peak gains in comparable windows. The distribution is heavily right-skewed, capturing the potential for a quiet quarter at the lower bound and a blockbuster outlier at the upper bound.
Strongest Arguments for Higher Values
Strongest Arguments for Lower Values
Key Uncertainties
I used Nasdaq’s official NBI constituent file dated May 1, 2026 as the closest public membership snapshot I could verify near May 12. It lists 263 constituents and includes many of the mid-cap names most relevant for this question, including ImmunityBio, Dyne, Edgewise, Immunovant, Scholar Rock, Spyre, Structure Therapeutics, Terns, Travere, and Vaxcyte. (nasdaq.com) For May 12 capitalization context, same-day component rankings show a large pool of NBI names clearly above the $3B cutoff, including Structure ($3.09B), Denali ($3.12B), Edgewise ($3.72B), Scholar Rock ($5.79B), Immunovant ($5.91B), Terns ($6.11B), CG Oncology ($6.11B), Vaxcyte ($7.8B), Praxis ($9.25B), Arrowhead ($10.95B), Axsome ($11.14B), and BridgeBio ($12.67B). (marketscreener.com)
The most important base-rate point is that the right tail is already very alive inside this universe. On May 12 component rankings, current NBI names above the cap threshold included ImmunityBio at +310.10% YTD, Erasca at +179.03%, Tango Therapeutics at +165.24%, Spyre Therapeutics at +129.06%, CG Oncology at +73.58%, and Apellis at +63.46%; Nasdaq’s constituent list shows these names are indeed NBI members. That does not mean the same stocks will lead again from May 12 onward, but it materially raises the base rate for a three-month extreme winner versus what a generic large-cap equity model would imply. (marketscreener.com)
There are also several live summer catalysts among eligible midcaps. Edgewise expects 12-week EDG-7500 HCM data in Q2 2026. Dyne says its BLA submission for U.S. accelerated approval of z-rostudirsen is on track for Q2 2026 and its confirmatory Phase 3 is also on track for Q2 2026. Scholar Rock’s apitegromab BLA has been accepted with a September 30, 2026 PDUFA date; the company says Catalent Indiana’s reinspection classification is expected within 90 days and that approval could be granted any time through September 30. Structure Therapeutics reported up to 16.3% weight loss in ACCESS II, plans ADA presentations in June 2026, expects initial oral amylin data in Q3 2026, and says aleniglipron Phase 3 is on track for Q3 2026. Terns expects pivotal-dose selection and end-of-Phase-2 FDA interaction for TERN-701 in mid-2026. (nasdaq.com)
M&A adds a separate tail. Gilead’s February 23, 2026 agreement to acquire Arcellx offered $115 per share in cash plus a CVR and represented a 68% premium to Arcellx’s 30-day VWAP; Gilead completed the acquisition on April 28. A similar takeover premium for any $3B-$8B eligible NBI constituent would immediately contend for the resolving maximum. (gilead.com)
My model therefore puts most weight on the $3B-$8B catalyst-rich midcaps rather than the mega-caps. I used a regime approach: a quiet tape where the winner is only a 25-50% mover; a normal catalyst season where the winner lands around 50-100%; a hot season where one name rerates into roughly 100-200%; and a small extreme tail for a blowout readout or takeover. Offsetting the bullish tail, many stocks have already rerated sharply in 2026, some important catalysts sit partly after the August 12 cutoff, and the largest NBI members are very large companies such as AstraZeneca, Amgen, Gilead, Vertex, and Regeneron. (marketscreener.com) My median forecast is about 72%. In the CDF I return, there is about a 31% chance the winning gain is 50% or less, about a 32% chance it exceeds 100%, about a 14% chance it exceeds 150%, and about a 1.5% chance it exceeds 300%. I leave a tiny residual probability above 600%, so the CDF at 600 is 0.9995 rather than 1.0.
I treated the eligible universe as the May 12, 2026 Nasdaq Biotechnology Index set, intersected with companies having market cap at or above $3 billion on May 12. Nasdaq’s methodology says the index includes all Nasdaq-listed biotechnology and pharmaceutical securities that meet the eligibility rules, selects constituents at the December reconstitution, and does not replace names outside reconstitution except through deletions for ineligibility or major corporate events. The Nasdaq Biotechnology overview page showed 254 components on May 12, 2026. (indexes.nasdaq.com)
That maintenance rule matters here because some obvious prior high-beta names are already gone from the May 12 universe. MSD completed its acquisition of Verona Pharma on October 7, 2025, and Gilead completed its acquisition of Arcellx on April 28, 2026. Those completed deals slightly thin the pool of obvious takeover candidates still available to set the maximum between now and August 12. (msd.com)
For the likely winner, I focused on the smaller end of the eligible set, because a 3-month maximum in biotech is usually driven by a single catalyst re-rating rather than by gradual multiple expansion in the biggest names. Representative eligible companies in that sweet spot include Viking Therapeutics at $3.62 billion, Beam Therapeutics at $3.26 billion, Denali Therapeutics at $3.63 billion, Scholar Rock at $6.26 billion, Protagonist Therapeutics at $7.05 billion, and Kymera Therapeutics at $8.15 billion. That is big enough to clear the screen, but still small enough for 50% to 100% moves on decisive news.
The current catalyst slate does support a meaningful right tail. Protagonist and Takeda have an August 2026 PDUFA goal date for rusfertide after positive Phase 3 data and priority review; Scholar Rock says apitegromab could be approved at any time through September 30, 2026; Beam expects initial BEAM-301 data in 2026 and is advancing BEAM-302 toward pivotal development; Viking just presented Phase 2 oral VK2735 data showing up to 12.2% weight loss at 13 weeks and said it plans to start oral Phase 3 later this year; Kymera has positive KT-621 Phase 1b data but no obvious pre-August registrational decision; BridgeBio has one NDA already filed and expects further NDA submissions in 1H 2026 and Q3 2026; and Axsome already added an FDA approval this year and is launching AUVELITY in Alzheimer’s disease agitation in June 2026. (sec.gov)
The sector backdrop is also supportive of an upside tail. McKinsey says life-sciences deal size increased nearly 63% in 2025 and that dealmaking gained momentum, while PwC expects 2026 biopharma dealmaking and biotech financing conditions to remain favorable though selective. That makes acquisition-driven outcomes more plausible than in a shut financing market, especially for derisked or strategically scarce assets. (mckinsey.com)
My base-rate view is therefore: first, it is very unlikely that the maximum gain is near zero, because across a universe this large at least one name usually catches either a positive tape or stock-specific bid; second, the most likely winning range is roughly 35% to 90%; third, 100% or more is materially possible but usually requires either a takeover premium or a genuinely transformative clinical or regulatory rerating; and fourth, 200% or more remains possible but needs a much rarer combination of low starting valuation, decisive catalyst, and strong follow-through buying. I also haircut the extreme right tail because the resolution uses adjusted closing prices rather than intraday highs, and because several obvious takeover names have already been removed before May 12.
I encoded that judgment as a five-part mixture: a tiny near-zero regime, plus four positive regimes centered around a modest winner, a strong winner, a major approval or takeout, and an extreme tail-event outcome. The resulting distribution has an approximate median around 65%, an interquartile range of roughly 38% to 103%, about a 20% chance of 125% or more, about a 5% chance of 200% or more, and only a low-single-digit chance of 300% or more. My single best summary judgment is that the final maximum is more likely than not to land well above 50%, but is not most likely to exceed 100%.
I started by fixing the eligible universe as of May 12, 2026. Nasdaq’s public NBI constituent file is dated May 1, 2026, and the official methodology says NBI constituents are selected at the annual December reconstitution, with quarterly rebalances and only event-driven deletions between scheduled dates. So the May 1 file should be very close to the May 12 constituent set, except for any just-completed corporate actions. (nasdaq.com)
After layering on the $3B market-cap rule, the universe is still large and still contains plenty of volatile mid-cap biotech names. Current market-cap data include BEAM at about $3.26B, ACAD at about $3.75B, CRNX at about $3.84B, TVTX at about $3.94B, APGE at about $5.78B, CGON at about $4.80B, PRAX at about $9.91B, NUVL at about $8.07B, and XENE at about $4.80B, alongside much larger names such as BNTX and MRNA. Because the question resolves to the single best performer and counts each stock’s highest close before August 12, the relevant distribution is the maximum across several dozen names, not the return of a typical constituent.
The near-term upside is concentrated in names with explicit before-August catalysts. Apogee expects APEX Part B 16-week data in Q2 2026. CG Oncology expects Phase 3 PIVOT-006 topline data in the first half of 2026 and CORE-008 cohort CX results at AUA on May 16. Praxis expects POWER1 Phase 3 topline results in Q2 2026. Nuvalent plans ASCO presentations in late May and early June while zidesamtinib remains under FDA review with a September 18, 2026 PDUFA date. Cogent has detailed Phase 3 PEAK data at ASCO on May 30 and multiple bezuclastinib NDAs advancing. Those are the names and setups most likely to dominate the maximum. (investors.apogeetherapeutics.com)
A few seemingly obvious high-beta candidates are less dangerous on the upside for this exact window than their raw volatility suggests. Centessa already agreed to be acquired by Lilly on March 31, 2026, which compresses upside toward deal spread. Immunovant reported on April 2, 2026 that its two Phase 3 TED studies failed to meet their primary endpoints. Beam and Xenon still have real optionality, but Beam’s next pivotal cohort initiation is scheduled for the second half of 2026, while Xenon’s biggest epilepsy de-risking step already occurred with positive X-TOLE2 topline data in March and NDA submission is targeted for the third quarter of 2026. (investors.centessa.com)
My model therefore uses a fat-tailed mixture rather than a narrow single distribution. Roughly speaking, I assign about 30% to a muted scenario where no stock breaks out and the winner is only in the 20% to 50% range, 45% to a scenario where one stock has a strong catalyst and the winner lands in the 50% to 100% range, 20% to a scenario where one name becomes a major winner in the 100% to 200% range, and about 5% to an extreme tail above 200% from a spectacular readout or takeout. That gives a median in the low 60s, about a 24% chance the maximum reaches at least 100%, about a 9% chance it reaches at least 150%, and only a very small chance above 300%. My point-forecast neighborhood is 55% to 75%, centered near a median of about 63%. The $3B floor mechanically trims the far-right tail versus a micro-cap biotech question, but the large number of eligible mid-caps keeps the overall maximum meaningfully above a typical single-stock forecast. (indexes.nasdaq.com)
I treated the official Nasdaq NBI component file dated May 1, 2026 as the best available proxy for the May 12, 2026 constituent set. Nasdaq’s methodology says NBI constituents are selected annually in December and are not replaced outside reconstitution except for deletions, and the index had 254 components around May 12. For forecasting, that means the May 1 roster should be very close to the May 12 roster absent a corporate-action removal. (indexes.nasdaq.com)
Using May 12 market-cap checks, the eligible pool is large and still includes many volatile mid-caps, not just mega-cap biopharma. Examples I verified above the $3B cutoff include Apogee at about $5.78B, CG Oncology at about $4.80B, Dyne at about $3.03B, Edgewise at about $3.64B, Praxis at about $9.91B, and Vaxcyte at about $7.54B. That matters because the resolution uses the single best performer and the highest adjusted close before August 12, so one outlier is enough.
Several of those eligible mid-caps have genuine near-term catalysts before resolution. Apogee expects APEX Part B 16-week atopic-dermatitis data in Q2 2026; Praxis expects POWER1 topline results in Q2 2026 and already has two accepted NDAs; Dyne plans a U.S. accelerated-approval BLA submission and Phase 3 initiation for z-rostudirsen in Q2 2026; Edgewise expects CIRRUS-HCM 12-week data in Q2 2026; and CG Oncology expects Phase 3 PIVOT-006 topline data in 1H 2026 plus CORE-008 data at AUA on May 16. This is a materially catalyst-rich setup for a three-month maximum-return question. (investors.apogeetherapeutics.com)
Funding is also strong at several likely movers, which reduces the chance that good data are immediately capped by financing anxiety: Apogee says runway into 2029 after a $403M equity raise; Praxis reported about $1.4B of cash and investments; CG Oncology about $1.1B; Edgewise about $499.6M; Beam about $1.2B. Still, I cap the far-right tail because many eligible names are already very large: Vertex was about $114.9B, Amgen about $182.9B, and Regeneron about $77.9B on May 12. A universe that includes several $3B-$10B names can certainly produce a 60%-150% winner, but a 300%+ three-month move is much harder once the starting market cap is already above $3B and the metric is adjusted close rather than intraday high. (investors.apogeetherapeutics.com)
My synthesis is therefore a distribution centered in the strong double-digit range with a meaningful but not dominant triple-digit tail. The CDF below implies a median around 78%, a 25th percentile around 55%, a 75th percentile around 110%, a 90th percentile around 154%, and a 95th percentile around 193%. Equivalently, I think the chance the winning stock exceeds 100% is around 30%, exceeds 150% is around 10%, exceeds 200% is around 4%-5%, and exceeds 300% is well under 1%. That is an inference from the roster size, market-cap mix, and catalyst calendar above, not a direct statement from any single source. (investors.apogeetherapeutics.com)
I treat 0.0% as the effective floor because the resolution compares each stocks highest adjusted close before Aug 12, 2026 with its adjusted close on May 12, 2026, so May 12 itself is already a candidate closing price unless the resolver interprets the window differently. For the universe, I used Nasdaqs public NBI constituent file dated 2026-05-01 as the closest fully visible official basket, noted that NBI showed 254 components on 2026-05-12, and adjusted for obvious post-05-01 events such as Terns, whose acquisition by MSD completed on 2026-05-05. That means the relevant field is still large, but it is not the full micro-cap biotech universe. (nasdaq.com)
Nasdaq methodology matters here because NBI includes ADRs, and for depositary receipts Nasdaq says references to the issuer use the actual depositary shares outstanding. The index is also modified market-cap weighted. So for screening the May 12 eligible set, I used Nasdaq-style listed-security market caps rather than informal global parent equity values for ADR names. (indexes.nasdaq.com)
The $3B cap floor removes the craziest micro-cap moonshot tail, but still leaves a lot of mid-cap event-risk. On May 12, representative eligible names ranged from Acadia at $3.75B, CG Oncology at $4.80B and Apogee at $5.78B up to mega-caps like Amgen at $182.94B, Gilead at $169.21B and Vertex at $114.90B. That mix pushes the distribution down versus an all-biotech universe because many very large constituents are simply too big to become the most explosive 3-month winner, but the $3B-$10B names can still re-rate sharply on trial data or M&A.
Most of the right tail comes from eligible mid-caps with real catalysts and enough size to qualify: PRAX was about $9.91B, NUVL $8.07B, PTGX $7.05B, SRRK $6.26B, CGON $4.80B, APGE $5.78B, GPCR $8.22B, and SMMT $14.69B on May 12. These are large enough to be in-scope, but still small enough that a single successful readout or bid can plausibly produce a 50%-100%+ move in a short window.
The catalyst calendar is unusually dense for the next three months. CG Oncology still expects PIVOT-006 phase 3 topline data in 1H 2026; Apogee expects APEX phase 2 Part B data in Q2 2026; Praxis expects POWER1 topline results in Q2 2026 and already has two NDAs under FDA review; Nuvalent plans ASCO data presentations in late May and early June and is preparing for a possible 2026 zidesamtinib launch pending review; Protagonist has a rusfertide PDUFA in August 2026; Scholar Rock has a September 30, 2026 PDUFA date that is outside the window but close enough to matter for pre-decision trading; Summit has already submitted a BLA for ivonescimab; and Insmed just reported BRINSUPRI first-quarter revenue of $207.9M and reiterated at least $1B of 2026 BRINSUPRI guidance. (globenewswire.com)
My inference from that setup is that the maximum winner is more likely than not to clear roughly +50%, because only one outlier is needed and several eligible names have company-specific readouts before Aug 12 or close enough to it to generate speculative run-ups. I still keep the distribution well below the wildest biotech anecdotes because the eligible set excludes sub-$3B names, many catalysts are already partly known or partly priced, and a large share of the universe consists of much larger commercial companies. Recent completed sector M&A, such as MSDs completed purchase of Terns on May 5, keeps a meaningful but not dominant acquisition tail in the forecast. (investors.apogeetherapeutics.com)
The resulting distribution is centered in the high-double-digits. In my model the 25th percentile is about 51%, the median about 76%, the 75th percentile about 115%, the 90th percentile about 163%, and the 95th percentile about 196%. I leave a thin tail above 300% because a single takeout or unexpectedly transformative clinical result could still create a very large closing-price rerating even in this >$3B universe, but that is meaningfully less likely here than in a no-cap-floor biotech basket. (msd.com)